Locations:
Search
Study shows high rate of hematologic responses, low rate of disease progression
Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma
Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population
Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.
Patient achieves complete remission from aggressive marginal zone lymphoma with liso-cel
Patient with TP53 mutation achieves full response with targeted therapy
Concurrent treatment necessary for addressing progressive disease and infection
Preliminary results suggest combination therapy with lisaftoclax improves survival with few adverse events in patients with AL amyloidosis and relapsed/refractory multiple myeloma
New system refines classification of cytogenetic abnormalities at time of response assessment and their clinical significance
Advertisement
Advertisement